Characterization of metoprolol biodegradation and its transformation products generated in activated sludge batch experiments and in full scale WWTPs

Water Research

Volumn 63, Issue , 2014, Pages 21-32

  Rubirola, A ^a   Llorca, M ^a   Rodriguez Mozaz, S ^a   Casas, N ^c   Rodriguez Roda, I ^a   Barcelo D ^a,b   Buttiglieri, G ^a  

^a UNIVERSITY OF GIRONA   (Spain)

^b INSTITUTE OF ENVIRONMENTAL ASSESSMENT AND WATER RESEARCH   (Spain)

^c HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

Biological treatment; Ecotoxicity; Metoprolol; Pharmaceuticals; Transformation products; Wastewater

Indexed keywords

ACTIVATED SLUDGE PROCESS; BIOCHEMICAL ENGINEERING; BIODEGRADATION; BIOLOGICAL WATER TREATMENT; BIOREACTORS; EFFLUENTS; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; TOXICITY; WASTEWATER TREATMENT;

ACTIVATED SLUDGE; BATCH EXPERIMENTS; BIOLOGICAL TRANSFORMATION; BIOLOGICAL TREATMENT; DIFFERENT TREATMENTS; ECOTOXICITY; EMERGING CONTAMINANT; METOPROLOL; TRANSFORMATION PRODUCTS; WASTE WATER TREATMENT PLANTS;

METABOLITES;

ALPHA HYDROXYMETOPROLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DRUG METABOLITE; METOPROLOL; METOPROLOL ACID; NORMETOPROLOL; UNCLASSIFIED DRUG; SEWAGE; WATER POLLUTANT;

ACTIVATED SLUDGE; BACTERIUM; BIODEGRADATION; BIOREACTOR; ECOTOXICOLOGY; MICROBIAL ACTIVITY; ORGANIC POLLUTANT; OXIC CONDITIONS; POLLUTANT REMOVAL; TOXICITY TEST; TRANSFORMATION; WASTE FACILITY;

ACTIVATED SLUDGE; ACUTE TOXICITY; ALIIVIBRIO FISCHERI; ANALYTIC METHOD; ARTICLE; BIODEGRADATION; BIOLUMINESCENCE; BIOTRANSFORMATION; CONTROLLED STUDY; ECOTOXICITY; EFFLUENT; LIMIT OF DETECTION; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MEMBRANE REACTOR; PRIORITY JOURNAL; TOXICITY TESTING; URBAN AREA; WASTE WATER TREATMENT PLANT; ANALYSIS; BIOREACTOR; BIOREMEDIATION; DRUG EFFECTS; LUMINESCENCE; METABOLISM; SEWAGE; WATER POLLUTANT;

ALIIVIBRIO FISCHERI; BIODEGRADATION, ENVIRONMENTAL; BIOREACTORS; CHROMATOGRAPHY, LIQUID; LUMINESCENT MEASUREMENTS; MASS SPECTROMETRY; METOPROLOL; SEWAGE; WASTE DISPOSAL, FLUID; WATER POLLUTANTS, CHEMICAL;

EID: 84903153158     PISSN: 00431354     EISSN: 18792448     Source Type: Journal    
DOI: 10.1016/j.watres.2014.05.031     Document Type: Article

References (35)

1. Alder A.C., Schaffner C., Majewsky M., Klasmeier J., Fenner K. Fate of β-blocker human pharmaceuticals in surface water: comparison of measured and simulated concentrations in the Glatt Valley Watershed, Switzerland. Water Res. 2010, 44(3):936-948.
2. APHA, A., WEF Standard Methods for the Examination of Water and Wastewater 2005.
3. Barclay V.K.H., Tyrefors N.L., Johansson I.M., Pettersson C.E. Chiral analysis of metoprolol and two of its metabolites, α-hydroxymetoprolol and deaminated metoprolol, in wastewater using liquid chromatography- tandem mass spectrometry. J. Chromatogr. 2012, 1269:208-217.
4. Boralli V.B., Coelho E.B., Cerqueira P.M., Lanchote V.L. Stereoselective analysis of metoprolol and its metabolites in rat plasma with application to oxidative metabolism. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 2005, 823(2):195-202.
5. Bouju H., Buttiglieri G., Malpei F. Perspectives of persistent organic pollutants (POPS) removal in an MBR pilot plant. Desalination 2008, 224(1-3):1-6.
6. Cleuvers M. Initial risk assessment for three beta-blockers found in the aquatic environment. Chemosphere 2005, 59(2):199-205.
7. Collado N., Buttiglieri G., Ferrando-Climent L., Rodriguez-Mozaz S., Barceló D., Comas J., Rodriguez-Roda I. Removal of ibuprofen and its transformation products: experimental and simulation studies. Sci. Total Environ. 2012, 433:296-301.
8. Collado N., Buttiglieri G., Marti E., Ferrando-Climent L., Rodriguez-Mozaz S., Barceló D., Comas J., Rodriguez-Roda I. Effects on activated sludge bacterial community exposed to sulfamethoxazole. Chemosphere 2013, 93(1):99-106.
9. Dong Z., Senn D.B., Moran R.E., Shine J.P. Prioritizing environmental risk of prescription pharmaceuticals. Regul. Toxicol. Pharmacol. 2013, 65(1):60-67.
10. Escher B.I., Bramaz N., Richter M., Lienert J. Comparative ecotoxicological Hazard assessment of beta-blockers and their human metabolites using a mode-of-action-based test battery and a QSAR Approach. Environ. Sci. Technol. 2006, 40:7402-7408.
11. Fatta-Kassinos D., Meric S., Nikolaou A. Pharmaceutical residues in environmental waters and wastewater: current state of knowledge and future research. Anal. Bioanal. Chem. 2011, 399(1):251-275.
12. Ferrando-Climent L., Collado N., Buttiglieri G., Gros M., Rodriguez-Roda I., Rodriguez-Mozaz S., Barceló D. Comprehensive study of ibuprofen and its metabolites in activated sludge batch experiments and aquatic environment. Sci. Total Environ. 2012, 438:404-413.
13. Gros M., Rodríguez-Mozaz S., Barceló D. Fast and comprehensive multi-residue analysis of a broad range of human and veterinary pharmaceuticals and some of their metabolites in surface and treated waters by ultra-high-performance liquid chromatography coupled to quadrupole-linear ion trap tandem mass spectrometry. J. Chromatogr. 2012, 1248:104-121.
14. Hernando M.D., Petrovic M., Fernàndez-Alba A.R., Barceló D. Analysis by liquid chromatography-electrospray ionization tandem mass spectrometry and acute toxicity evaluation for β-blockers and lipid-regulating agents in wastewater samples. J. Chromatogr. 2004, 1046(1-2):133-140.
15. Hogenboom A.C., van Leerdam J.A., de Voogt P. Accurate mass screening and identification of emerging contaminants in environmental samples by liquid chromatography- hybrid linear ion trap orbitrap mass spectrometry. J. Chromatogr. 2009, 1216(3):510-519.
16. Huerta-Fontela M., Galceran M.T., Ventura F. Occurrenceand removal of pharmaceuticals and hormones through drinking water treatment. Water Res. 2011, 45(3):1432-1442.
17. Hughes S.R., Kay P., Brown L.E. Global synthesis and critical evaluation of pharmaceutical data sets collected from river systems. Environ. Sci. Technol. 2013, 47(2):661-677.
18. ISO11348-3 Determination of the Inhibitory Effect of Water Samples on the Light Emission of Vibrio fischeri (Luminescent Bacteria Test) 1998.
19. Kern S., Baumgartner R., Helbling D.E., Hollender J., Singer H., Loos M.J., Schwarzenbach R.P., Fenner K. A tiered procedure for assessing the formation of biotransformation products of pharmaceuticals and biocides during activated sludge treatment. J. Environ. Monit. 2012, 12:2100-2111.
20. Kujawa-Roeleveld K. Biodegradability and Fate of Pharmaceutical Impact Compounds in Different Treatment Processes 2008, SWITCH project. Sustainable Water Management in the City of the Future. http://www.switchurbanwater.eu.
21. Laboratory S.A.T. Aquatic Toxicity Testing in Ireland 2010.
22. Lacey C., Basha S., Morrissey A., Tobin J. Occurrence of pharmaceutical compounds in wastewater process streams in Dublin, Ireland. Environ. Monit. Assess. 2012, 184(2):1049-1062.
23. Langford K., Thomas K.V. Input of selected human pharmaceutical metabolites into the Norwegian aquatic environment. J. Environ. Monit. 2011, 13:416-421.
24. Maurer M., Escher B.I., Richle P., Schaffner C., Alder A.C. Elimination of beta-blockers in sewage treatment plants. Water Res. 2007, 41(7):1614-1622.
25. Musson S.E., Campo P., Tolaymat T., Suidan M., Townsend T.G. Assessment of the anaerobic degradation of six active pharmaceutical ingredients. Sci. Total Environ. 2010, 408(9):2068-2074.
26. Oosterhuis M., Sacher F., ter Laak T.L. Prediction of concentration levels of metformin and other high consumption pharmaceuticals in wastewater and regional surface water based on sales data. Sci. Total Environ. 2013, 442:380-388.
27. Orias F., Perrodin Y. Characterisation of the ecotoxicity of hospital effluents: a review. Sci. Total Environ. 2013, 454-455:250-276.
28. Radjenovic J., Pérez S., Petrovic M., Barceló D. Identification and structural characterization of biodegradation products of atenolol and glibenclamide by liquid chromatography coupled to hybrid quadrupole time-of-flight and quadrupole ion trap mass spectrometry. J. Chromatogr. 2008, 1210(2):142-153.
29. Scheurer M., Ramil M., Metcalfe C., Groh S., Ternes T. The challenge of analyzing beta-blocker drugs in sludge and wastewater. Anal. Bioanal. Chem. 2010, 396(2):845-856.
30. Selke S., Hühnerfuss H. Detection and stereoselective analysis of three metoprolol metabolites in STP-effluent samples. Organohalogen Compd. 2009, 71:447-451.
31. Triebskorn R., Casper H., Scheil V., Schwaiger J. Ultrastructural effects of pharmaceuticals (carbamazepine, clofibric acid, metoprolol, diclofenac) in rainbow trout (Oncorhynchus mykiss) and common carp (Cyprinus carpio). Anal. Bioanal. Chem. 2007, 387(4):1405-1416.
32. US-EPA National Whole Effluent Toxicity (WET)Implementation Guidance Under the NPDES Program - DRAFT 2004.
33. Veloutsou S., Bizani E., Fytianos K. Photo-Fenton decomposition of two pharmaceutical compounds; atenolol and metoprolol. Proceedings of the 12th International Conference on Environmental Science and Technology. Rhodes, Greece, 8-10 September 2011 2011.
34. Verlicchi P., Al Aukidy M., Zambello E. Occurrence of pharmaceutical compounds in urban wastewater: removal, mass load and environmental risk after a secondary treatment- A review. Sci. Total Environ. 2012, 429:123-155.
35. Wick A., Fink G., Joss A., Siegrist H., Ternes T.A. Fate of beta blockers and psycho-active drugs in conventional wastewater treatment. Water Res. 2009, 43(4):1060-1074.